Follow ups of patients in AK1830 Phase II Studies

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210566

Enrollment

Registered

2022-01-21

Start date

2022-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis, chronic lumbar pain

Interventions

diagnostic imaging (No study drug administration during the follow up)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who provided written informed consent to participate in the clinical study and who met all of the following criteria [1] Patients who participated in the AK1830 Phase II Study and were deemed to require follow up. [2] Patients who fully understand the contents of the study and are capable of providing informed consent

Exclusion criteria

Exclusion criteria: Patients who met any of the following criteria are to be excluded. [1] Patients who have received their long-term safety outcomes in the AK1830 Phase II Study [2] Patients deemed by the investigator or sub-investigator to be unsuitable for study participation

Design outcomes

Primary

Measure	Time frame
image evaluations	—

Contacts

Public ContactContact for Clinical Trial Information

ASAHI KASEI THERAPEUTICS CORPORATION

ct-info@om.asahi-kasei.co.jp+81-3-6699-3600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026